Ivax highlights Paxene safety compared to Taxol at advisory committee review for AIDS-related KS.
Executive Summary
IVAX HIGHLIGHTS PAXENE SAFETY PROFILE COMPARED TO TAXOL at the Sept. 19 Oncologic Drugs Advisory Committee meeting review of Paxene for treatment of AIDS-related Kaposi's sarcoma. While Paxene's "tumor response rate is similar to that of Taxol when used at the same dose and schedule," Paxene's "safety is no worse, and in certain adverse events, may be better than that of Taxol," Baker Norton Medical Director Gregory Harriman asserted.